4D Molecular Therapeutics...

3.25
-0.17 (-4.97%)
At close: Apr 24, 2025, 3:59 PM
3.27
0.46%
After-hours: Apr 24, 2025, 07:01 PM EDT

4D Molecular Therapeutics Statistics

Share Statistics

4D Molecular Therapeutics has 46.3M shares outstanding. The number of shares has increased by -10.45% in one year.

Shares Outstanding 46.3M
Shares Change (YoY) -10.45%
Shares Change (QoQ) 0.16%
Owned by Institutions (%) 84.35%
Shares Floating 39.64M
Failed to Deliver (FTD) Shares 10.43K
FTD / Avg. Volume 1.26%

Short Selling Information

The latest short interest is 5.06M, so 10.94% of the outstanding shares have been sold short.

Short Interest 5.06M
Short % of Shares Out 10.94%
Short % of Float 11.38%
Short Ratio (days to cover) 7.16

Valuation Ratios

The PE ratio is -1.87 and the forward PE ratio is -0.9. 4D Molecular Therapeutics's PEG ratio is -0.12.

PE Ratio -1.87
Forward PE -0.9
PS Ratio 8120.72
Forward PS 1.2
PB Ratio 0.59
P/FCF Ratio -2.23
PEG Ratio -0.12
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for 4D Molecular Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 14.92, with a Debt / Equity ratio of 0.05.

Current Ratio 14.92
Quick Ratio 14.92
Debt / Equity 0.05
Debt / EBITDA -0.13
Debt / FCF -0.18
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $163
Profits Per Employee $-708.67K
Employee Count 227
Asset Turnover 0
Inventory Turnover n/a

Taxes

Income Tax 0
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by -85.9% in the last 52 weeks. The beta is 2.88, so 4D Molecular Therapeutics's price volatility has been higher than the market average.

Beta 2.88
52-Week Price Change -85.9%
50-Day Moving Average 3.79
200-Day Moving Average 9.05
Relative Strength Index (RSI) 52.52
Average Volume (20 Days) 830.42K

Income Statement

In the last 12 months, 4D Molecular Therapeutics had revenue of 37K and earned -160.87M in profits. Earnings per share was -2.98.

Revenue 37K
Gross Profit 37K
Operating Income -187.84M
Net Income -160.87M
EBITDA -187.84M
EBIT -187.84M
Earnings Per Share (EPS) -2.98
Full Income Statement

Balance Sheet

The company has 149.34M in cash and 24.61M in debt, giving a net cash position of 124.73M.

Cash & Cash Equivalents 149.34M
Total Debt 24.61M
Net Cash 124.73M
Retained Earnings -576.2M
Total Assets 560.38M
Working Capital 405.78M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -134.59M and capital expenditures 0, giving a free cash flow of -134.59M.

Operating Cash Flow -134.59M
Capital Expenditures 0
Free Cash Flow -134.59M
FCF Per Share -2.49
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -507678.38% and -434778.38%.

Gross Margin 100%
Operating Margin -507678.38%
Pretax Margin -434778.38%
Profit Margin -434778.38%
EBITDA Margin -507678.38%
EBIT Margin -507678.38%
FCF Margin -363743.24%

Dividends & Yields

FDMT does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for FDMT is $35.5, which is 938% higher than the current price. The consensus rating is "Buy".

Price Target $35.5
Price Target Difference 938%
Analyst Consensus Buy
Analyst Count 8
Stock Forecasts

Scores

Altman Z-Score 0.19
Piotroski F-Score 2